Oxaliplatin News and Research

RSS
Amgen announces results from pivotal Phase 3 "408" trial of Vectibix

Amgen announces results from pivotal Phase 3 "408" trial of Vectibix

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

Æterna Zentaris commences perifosine Phase 3 registration trial

Æterna Zentaris commences perifosine Phase 3 registration trial

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

Par Pharmaceutical, sanofi-aventis resolve patent litigation case

Par Pharmaceutical, sanofi-aventis resolve patent litigation case

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

Physicians increase prescription of new biologics

Physicians increase prescription of new biologics

Hospira reaches legal settlement with Sanofi-Aventis over oxaliplatin injection patent litigation

Hospira reaches legal settlement with Sanofi-Aventis over oxaliplatin injection patent litigation

APP, Fresenius Kabi and sanofi-aventis sign license and settlement agreements

APP, Fresenius Kabi and sanofi-aventis sign license and settlement agreements

Teva Pharmaceutical Industries settles generic eloxatin patent infringement litigation

Teva Pharmaceutical Industries settles generic eloxatin patent infringement litigation

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

Stage IV colorectal cancer: Therapy that improves overall survival over IFL/bevacizumab will earn 60% patient share

Stage IV colorectal cancer: Therapy that improves overall survival over IFL/bevacizumab will earn 60% patient share

Latest treatment options for colorectal cancer highlighted at NCCN Annual Conference

Latest treatment options for colorectal cancer highlighted at NCCN Annual Conference

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

CINJ researchers test malaria drug for colorectal cancer treatment

CINJ researchers test malaria drug for colorectal cancer treatment

Teva Pharmaceutical Industries announces fourth-quarter and full-year 2009 financial results

Teva Pharmaceutical Industries announces fourth-quarter and full-year 2009 financial results

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

Erbitux improves survival of mCRC patients with KRAS wild-type tumors

Erbitux improves survival of mCRC patients with KRAS wild-type tumors

Final data from Poniard Pharmaceuticals' randomized Phase 2 trial of picoplatin announced

Final data from Poniard Pharmaceuticals' randomized Phase 2 trial of picoplatin announced